Occam Places Natalie Holles as CEO of Aura Biosciences
In May 2026, Occam Global placed Natalie Holles as CEO of Aura Biosciences (NASDAQ: AURA).
Natalie is a proven biopharma CEO with a track record of building and leading innovative companies through critical inflection points. Most recently, she served as President and CEO of Third Harmonic Bio, where she guided the company through its IPO and advanced its clinical pipeline. Prior to that, she held senior leadership roles at Vertex Pharmaceuticals, including Head of Global Rare Diseases, where she played a key role in commercializing transformative therapies.
Natalie holds a bachelor degree in Human Biology from Stanford University and an MA in Molecular, Cellular and Developmental Biology from the University of Colorado Boulder.
DISCOVER OCCAM GLOBAL
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies.
Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.